United Therapeutics (UTHR) Other financing activities (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Other financing activities data on file, last reported at $68.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities rose 311.45% year-over-year to $68.3 million; the trailing twelve-month figure through Mar 2026 stood at $225.6 million (up 123.15% YoY), and the FY2025 full-year result was $173.9 million, up 2188.16% from the prior year.
• Other financing activities slipped to $68.3 million in Q1 2026, from $99.0 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $99.0 million in Q4 2025 to a low of -$84.1 million in Q4 2023.
• A 5-year average of $19.0 million and a median of $18.1 million in 2025 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities slumped 211.48% in 2023 and soared 99100.0% in 2025, its largest moves.
• Tracing UTHR's Other financing activities over 5 years: stood at -$27.0 million in 2022, then tumbled by 211.48% to -$84.1 million in 2023, then soared by 99.88% to -$100000.0 in 2024, then soared by 99100.0% to $99.0 million in 2025, then slumped by 31.01% to $68.3 million in 2026.
• Business Quant data shows UTHR's Other financing activities at $68.3 million in Q1 2026, $99.0 million in Q4 2025, and $40.2 million in Q3 2025.